Ensign Peak Advisors
PASG icon

Ensign Peak Advisors’s Passage Bio PASG Stock Holding History

Ensign Peak Advisors’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-664
Closed -$41K – 2194
2022
Q1 		$41K Hold
664
– – ﹤0.01% 2146
2021
Q4 		$84K Buy
+664
New +$108K ﹤0.01% 2092
2021
Q3 		– Sell
-1,283
Closed -$340K – 1872
2021
Q2 		$340K Hold
1,283
– – ﹤0.01% 1657
2021
Q1 		$448K Buy
+1,283
New +$548K ﹤0.01% 1615

Other funds holding PASG

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ensign Peak Advisors's PASG Position: Q2 2022 in Review

Ensign Peak Advisors sold out of Passage Bio (PASG) in Q2 2022, closing a stake of 664 shares — an estimated $41K sold.

Ensign Peak Advisors first reported a position in PASG in Q1 2021 and held it in 4 quarters. The position peaked at $448K in Q1 2021. 85 funds tracked by Wall St. Rank hold PASG as of Q2 2022.

  • Ensign Peak Advisors reported no remaining Passage Bio position as of Q2 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 664 Passage Bio shares in Q2 2022, an estimated $41K.
  • Ensign Peak Advisors first reported a position in Passage Bio in Q1 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Passage Bio position peaked at $448K in Q1 2021.
  • 85 funds tracked by Wall St. Rank held Passage Bio as of Q2 2022.

Based on Ensign Peak Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.